Stonvex
Discover
  • Dashboard
  • World News
  • Stock News
  • Rankings
  • Quant Picks
  • Screener
Markets
  • Heatmap
  • Gainers & Losers
Tools
  • Compare
  • Calendar
  • Community
HomeRankingsScreenerPortfolioCommunity
Stonvex
Log inGet Started
← Back to search

NVO

Live
Real-time chart · IB-grade AI research · Polygon.io data feed
Set alertSave
  • Overview
  • Financials
  • Filings
  • Short Interest
  • Ownership
  • Ratings
  • Peers
  • Options
  • News
✦
Stonvex AI

NVO

AI Research Report

Powered by Claude

Ready to analyze NVO

Runs the full IB-grade framework: Narrative, Reverse DCF, Comps, Sensitivity, and Deal Radar. Takes 20–40 seconds.

Free preview · 3 reports / hour · No sign-up required

Earnings

Next report date, year-over-year trend, and recent quarter history.

Earnings history activates with Polygon. When configured, this panel shows the next report date, consensus EPS/revenue, and the last 4 quarters of actual-vs-estimate.

Quant Grades

6-factor scoring with sector-relative rank. Updated daily.

C+
Stonvex Quant Grade
50.0/ 100
Rank-normalised composite of 6 factors, updated every 60 seconds.
Volume
C+
50 / 100

Today's volume vs prior session average.

Volatility
C+
50 / 100

Absolute daily price move vs peers.

News Flow
C+
50 / 100

24h article count relative to the universe.

Sentiment
C+
50 / 100

AI-classified polarity of recent news.

Dollar Flow
C+
50 / 100

Today's dollar turnover (volume × VWAP).

Relative Strength
C+
50 / 100

Signed daily return vs the rest of the universe.

Financial statements

Most recent quarterly filings sourced directly from SEC EDGAR.

Financial statements activate with Polygon. The Developer plan includes quarterly and annual filings sourced directly from SEC EDGAR.

Corporate events

Similar stocks

View all Biotech →
MRNA
Moderna
$42.80
+5.29%
LLY
Eli Lilly
$810.50
+2.30%
UNH
UnitedHealth
$485.20
-2.51%
BNTX
BioNTech
—
—
REGN
Regeneron
—
—
VRTX
Vertex Pharma
—
—
Share this analysis

Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.

Stonvex

AI-powered stock research for US equities.

whgksdhr1111@naver.com

Product

  • Rankings
  • Quant Picks
  • Screener
  • Markets
  • Compare
  • Calendar

Company

  • About Stonvex
  • Pricing & Plans
  • Community
  • Help & FAQ
  • Contact Us

Legal

  • Terms of Service
  • Privacy Policy
  • Privacy Consent
  • Disclaimer
  • Notices & Updates

© 2026 Stonvex. All rights reserved.

This site is for informational purposes only. Not investment advice. Past performance does not guarantee future results.

Latest news

Factor Grades

5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.

Novo Nordisk A/S

Novo Nordisk A/S

Pharmaceuticals·OMX NORDIC EXCHANGE COPENHAGEN A/S·DK·IPO 1974-05-17

Analyst Consensus

Buy
Based on 37 analysts
Period: 2026-04-01
12 Buy (32%)23 Hold (62%)2 Sell (5%)
Rating Distribution
Strong Buy
5
Buy
7
Hold
23
Sell
1
Strong Sell
1
Trend
2026-04
12/23/2
2026-03
13/19/2
2026-02
18/13/3
2026-01
18/11/3
No recent insider activity on SEC EDGAR.
📅 Earnings in 22d (May 6)
OMX NORDIC EXCHANGE COPENHAGEN A/SAfter-hours
Novo Nordisk A/S
Pharmaceuticals
$39.16
$1.18 (+3.11%)
After-hrs · vs prev close $37.98
Open
$38.77
Prev close
$37.98
Day range
$38.73 – $39.23
52W range
$224.25 – $533.40
Mkt cap
$1.07T
P/E
10.4
EPS
$23.03
Beta
1.72

Factor Grades

View details →
B-
Overall score: 64/100
B
Valuation
B-
Growth
A
Profitability
D+
Momentum
B-
Financial Health

Fundamentals

Valuation
Market Cap
$1.07T
P/E (TTM)
10.44S&P avg ~22
P/S (TTM)
3.46S&P avg ~2.8
P/B
7.44S&P avg ~4.5
P/FCF
16.40S&P avg ~26
EPS (TTM)
$23.03
Book/sh
$43.71
Cash/sh
$6.07
Profitability
Gross Margin
80.98%
avg ~45%
Operating Margin
41.30%avg ~15%
Net Margin
33.14%avg ~12%
ROE
61.10%avg ~18%
ROA
20.22%avg ~7%
ROI
36.56%
Payout Ratio
68.98%
FCF/sh
—
Growth & Health
Rev Growth YoY
6.43%
Rev Growth 5Y
19.48%
EPS Growth YoY
1.76%
EPS Growth 5Y
20.66%
Current Ratio
—
Quick Ratio
0.57
Debt/Equity
—
LT Debt/Eq
—
Trading & Dividends
Beta
1.72
52W High
$533.40
52W Low
$224.25
Avg Vol (10D)
6.12M
Avg Vol (3M)
7.92M
Div Yield
4.91%
Div/sh (TTM)
—
Analyst
Buy (37)
Price Performance
5D+1.34%
MTD+3.18%
3M-35.67%
6M-35.81%
YTD-26.75%
1Y+67.26%
  • SeekingAlpha·8h ago

    Baird International And Global Growth Funds Q1 2026 Portfolio Activity

    For the Baird Chautauqua International Growth Fund, 60% of companies that reported earnings during the quarter were in line with or exceeded consensus estimates.

  • Benzinga·8h ago

    Stocks Rally Toward Record Highs, Oil Crashes 7% As Iran Talks Show Progress: What's Moving Markets Tuesday?

    U.S. equities rally to pre-war highs and crude plunges nearly 7% as U.S. Vice President JD Vance cites "a lot of progress" in Iran talks.

  • Benzinga·8h ago

    Move Over Novo Nordisk - This Small Company Study Flags Edge In Fatty Liver Drug

    Hoth Therapeutics shares jump after HT-VA data show GDNF impacts liver fat genes and outperforms semaglutide markers in MAFLD research.

  • SeekingAlpha·11h ago

    Novo Nordisk: Intense Competition Within The GLP-1 Duopoly

    Novo Nordisk (NVO) stock is down ~75% from highs; learn why strong free cash flow, AA balance sheet, and GLP‑1 growth support a Buy—read the full analysis here.

  • Benzinga·11h ago

    Novo Nordisk Gets U.K.'s Medicines And Healthcare Products Regulatory Agency Approval For New, Single 7.2Mg Dose Of Wegovy

    https://www.gov.uk/government/news/single-dose-72mg-semaglutide-wegovy-pen-approved-to-treat-adult-patients-with-obesity

  • SeekingAlpha·1d ago

    Novo Nordisk: Don't Stop Purchasing The Dip

    Novo Nordisk remains a compelling investment despite share price weakness, driven by robust innovation and a resilient, diversified drug pipeline. Learn more about NVO stock here.

  • SeekingAlpha·4d ago

    Conagra Vs. Hormel: 2 Beaten‑Down, High‑Yield Food Giants Face Off

    Conagra Brands, Inc. and Hormel Foods Corporation are Buy-rated: defensive dividend stocks with protein-focused brands. Click for more on CAG and HRL shares.

  • SeekingAlpha·4d ago

    EDEN: No Longer Expensive, But Not Much Incentive To Turn Bullish Either

    iShares MSCI Denmark ETF outlook: Danish stocks face political uncertainty & weak confidence. Read here for more analysis on EDEN ETF.

  • View all news →